Date: 2013-09-19
Type of information: Development agreement
Compound: companion diagnostic tests
Company: Boehringer Ingelheim (Germany) Ventana Medical Systems (USA), a member of the Roche Group (Switzerland)
Therapeutic area: Cancer - Oncology
Type agreement: development
Action mechanism:
Disease:
Details: * On September 19, 2013, Ventana Medical Systems, a member of the Roche Group, and Boehringer Ingelheim have announced that they have entered into an agreement to collaborate on the development of companion diagnostic tests for Boehringer Ingelheim oncology programs.
As part of the agreement, Ventana will utilize its immunohistochemistry technology platform, experience and expertise in companion diagnostic development and premarket approval submissions to support Boehringer Ingelheim\'s personalized medicine healthcare strategies for cancer drug development.
Financial terms:
Latest news:
